These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 29173297)

  • 21. Facial nerve palsy, Kawasaki disease, and coronary artery aneurysm.
    Stowe RC
    Eur J Paediatr Neurol; 2015 Sep; 19(5):607-9. PubMed ID: 26101056
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [Reply to questions regarding diagnosis and treatment of Kawasaki disease].
    Wang HW
    Zhonghua Er Ke Za Zhi; 2006 May; 44(5):337-8. PubMed ID: 16780708
    [No Abstract]   [Full Text] [Related]  

  • 23. Anakinra Treatment in Patients with Acute Kawasaki Disease with Coronary Artery Aneurysms: A Phase I/IIa Trial.
    Yang J; Jain S; Capparelli EV; Best BM; Son MB; Baker A; Newburger JW; Franco A; Printz BF; He F; Shimizu C; Hoshino S; Bainto E; Moreno E; Pancheri J; Burns JC; Tremoulet AH
    J Pediatr; 2022 Apr; 243():173-180.e8. PubMed ID: 34953816
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Infliximab for intensification of primary therapy for patients with Kawasaki disease and coronary artery aneurysms at diagnosis.
    Miyata K; Bainto EV; Sun X; Jain S; Dummer KB; Burns JC; Tremoulet AH
    Arch Dis Child; 2023 Oct; 108(10):833-838. PubMed ID: 37258054
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Rationale and study design for a phase I/IIa trial of anakinra in children with Kawasaki disease and early coronary artery abnormalities (the ANAKID trial).
    Tremoulet AH; Jain S; Kim S; Newburger J; Arditi M; Franco A; Best B; Burns JC
    Contemp Clin Trials; 2016 May; 48():70-5. PubMed ID: 27080929
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Initial intravenous gammaglobulin treatment failure in Kawasaki disease.
    Wallace CA; French JW; Kahn SJ; Sherry DD
    Pediatrics; 2000 Jun; 105(6):E78. PubMed ID: 10835091
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Heart Rate, Responsiveness to Intravenous Immunoglobulin, and Coronary Artery Aneurysms in Kawasaki Disease.
    Miyakoshi C; Yamamoto Y; Yamakawa M; Fukuhara S
    J Pediatr; 2018 Sep; 200():160-165.e5. PubMed ID: 29793867
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Correlation of Coronary Artery Abnormalities with Fever Pattern in Patients with Kawasaki Disease.
    Tanaka A; Inoue M; Hoshina T; Koga H
    J Pediatr; 2021 Sep; 236():95-100. PubMed ID: 34019881
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Refractory Kawasaki disease with coronary aneurysms treated with infliximab].
    Salguero JS; Durán DG; Peracaula CS; Iznardi CR; Tardío JO
    An Pediatr (Barc); 2010 Nov; 73(5):268-71. PubMed ID: 20678974
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy.
    Hashino K; Ishii M; Iemura M; Akagi T; Kato H
    Pediatr Int; 2001 Jun; 43(3):211-7. PubMed ID: 11380911
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Kawasaki disease.
    Sundel RP
    Rheum Dis Clin North Am; 2015; 41(1):63-73, viii. PubMed ID: 25399940
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy and limitation of infliximab treatment for children with Kawasaki disease intractable to intravenous immunoglobulin therapy: report of an open-label case series.
    Mori M; Imagawa T; Hara R; Kikuchi M; Hara T; Nozawa T; Miyamae T; Yokota S
    J Rheumatol; 2012 Apr; 39(4):864-7. PubMed ID: 22337241
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Infliximab versus second intravenous immunoglobulin for treatment of resistant Kawasaki disease in the USA (KIDCARE): a randomised, multicentre comparative effectiveness trial.
    Burns JC; Roberts SC; Tremoulet AH; He F; Printz BF; Ashouri N; Jain SS; Michalik DE; Sharma K; Truong DT; Wood JB; Kim KK; Jain S;
    Lancet Child Adolesc Health; 2021 Dec; 5(12):852-861. PubMed ID: 34715057
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Randomized trial of pulsed corticosteroid therapy for primary treatment of Kawasaki disease.
    Newburger JW; Sleeper LA; McCrindle BW; Minich LL; Gersony W; Vetter VL; Atz AM; Li JS; Takahashi M; Baker AL; Colan SD; Mitchell PD; Klein GL; Sundel RP;
    N Engl J Med; 2007 Feb; 356(7):663-75. PubMed ID: 17301297
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Association of Severity of Coronary Artery Aneurysms in Patients With Kawasaki Disease and Risk of Later Coronary Events.
    Miura M; Kobayashi T; Kaneko T; Ayusawa M; Fukazawa R; Fukushima N; Fuse S; Hamaoka K; Hirono K; Kato T; Mitani Y; Sato S; Shimoyama S; Shiono J; Suda K; Suzuki H; Maeda J; Waki K; ; Kato H; Saji T; Yamagishi H; Ozeki A; Tomotsune M; Yoshida M; Akazawa Y; Aso K; Doi S; Fukasawa Y; Furuno K; Hayabuchi Y; Hayashi M; Honda T; Horita N; Ikeda K; Ishii M; Iwashima S; Kamada M; Kaneko M; Katyama H; Kawamura Y; Kitagawa A; Komori A; Kuraishi K; Masuda H; Matsuda S; Matsuzaki S; Mii S; Miyamoto T; Moritou Y; Motoki N; Nagumo K; Nakamura T; Nishihara E; Nomura Y; Ogata S; Ohashi H; Okumura K; Omori D; Sano T; Suganuma E; Takahashi T; Takatsuki S; Takeda A; Terai M; Toyono M; Watanabe K; Watanabe M; Yamamoto M; Yamamura K
    JAMA Pediatr; 2018 May; 172(5):e180030. PubMed ID: 29507955
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Real-world Safety and Effectiveness of Infliximab in Pediatric Patients With Acute Kawasaki Disease: A Postmarketing Surveillance in Japan (SAKURA Study).
    Miura M; Kobayashi T; Igarashi T; Hamada H; Iwata N; Sasaki Y; Matsukawa M; Sato N; Kubo H; Takei S
    Pediatr Infect Dis J; 2020 Jan; 39(1):41-47. PubMed ID: 31815838
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeted use of prednisolone with the second IVIG dose for refractory Kawasaki disease.
    Kimura M; Harazaki M; Fukuoka T; Asakura I; Sakai H; Kamimaki T; Ohkawara I; Akiyama N; Tsurui S; Iwashima S; Shimomura M; Morishita H; Meguro T; Seto S
    Pediatr Int; 2017 Apr; 59(4):397-403. PubMed ID: 27743415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Role of the Egami Score in Predicting Intravenous Immunoglobulin Resistance in Kawasaki Disease Among Different Ethnicities.
    Loomba RS; Raskin A; Gudausky TM; Kirkpatrick E
    Am J Ther; 2016; 23(6):e1293-e1299. PubMed ID: 25611359
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prevalence of coronary artery lesions on the initial echocardiogram in Kawasaki syndrome.
    Baer AZ; Rubin LG; Shapiro CA; Sood SK; Rajan S; Shapir Y; Romano A; Bierman FZ
    Arch Pediatr Adolesc Med; 2006 Jul; 160(7):686-90. PubMed ID: 16818833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Kawasaki disease: Medical therapies.
    Newburger JW
    Congenit Heart Dis; 2017 Sep; 12(5):641-643. PubMed ID: 28580631
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.